Synergy Pharmaceuticals Inc
Rodman & Renshaw analyst Ram Selvaraju was out pounding the table on Synergy Pharmaceuticals, reiterating a Buy rating and price target of $20, which represents a potential upside of 406% from where the stock is currently trading.
Selvaraju wrote, “We believe recent weakness in Synergy’s stock price provides a prime opportunity for investors to build positions ahead of the submission of plecanatide in chronic idiopathic constipation (CIC), which we anticipate being filed within the coming days. The firm is also slated to report results near-term from two pivotal trials of plecanatide in constipation-predominant irritable bowel syndrome (IBS-C). Positive data has also recently been reported with Synergy’s second pipeline candidate, dolcanatide, which was being tested in a Phase 1b trial in ulcerative colitis.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ram Selvaraju has a yearly average return of 0.5% and a 42.1% success rate. Selvaraju has a -33.1% average return when recommending SGYP, and is ranked #1529 out of 3608 analysts.
All the 5 analysts polled by TipRanks rate Synergy Pharmaceuticals stock a Buy. With a return potential of 280%, the stock’s consensus target price stands at $15.
ZIOPHARM Oncology Inc.
In addition, Mizuho Securities analyst Eric Criscuolo reiterated a Neutral rating on shares of Ziopharm Oncology, while reducing the price target to $6.00 (from $10), which represents a slight upside potential from current levels.
Criscuolo explained, “We’re lowering our PT from $10 to $6, taking down our valuation multiples given market conditions and lowering long term revenue to address intensifying competition. We think ZIOP’s has rolled out an aggressive, intriguing pipeline and development strategy, but we need to see more clinical data before we become more constructive, so we remain on the sidelines.”
According to TipRanks.com, analyst Eric Criscuolo has a yearly average return of -15.7% and a 20% success rate. Criscuolo is ranked #3134 out of 3608 analysts.